X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (96) 96
index medicus (93) 93
heterocyclic compounds, 2-ring - therapeutic use (80) 80
heterocyclic compounds, 2-ring - pharmacology (75) 75
animals (73) 73
male (53) 53
female (47) 47
pharmacology & pharmacy (34) 34
mice (31) 31
heterocyclic compounds, 2-ring - chemistry (30) 30
cell line, tumor (28) 28
rats (27) 27
middle aged (21) 21
analysis (18) 18
cancer (18) 18
double-blind method (18) 18
heterocyclic compounds, 2-ring - adverse effects (18) 18
treatment outcome (18) 18
aged (17) 17
antineoplastic agents - pharmacology (17) 17
heterocyclic compounds, 2-ring - administration & dosage (17) 17
structure-activity relationship (17) 17
adult (16) 16
chemistry, medicinal (16) 16
dose-response relationship, drug (16) 16
administration, oral (15) 15
amidines - therapeutic use (15) 15
biochemistry & molecular biology (15) 15
heterocyclic compounds, 2-ring - chemical synthesis (15) 15
heterocyclic compounds, 2-ring - pharmacokinetics (15) 15
activation (14) 14
apoptosis (14) 14
cell proliferation - drug effects (14) 14
disease models, animal (13) 13
inhibitors (13) 13
nitric oxide (13) 13
nitric oxide synthase - antagonists & inhibitors (13) 13
oncology (13) 13
research (13) 13
diabetes mellitus, type 2 - drug therapy (12) 12
expression (12) 12
heterocyclic compounds (12) 12
multidisciplinary sciences (12) 12
proteins (12) 12
rats, sprague-dawley (12) 12
apoptosis - drug effects (11) 11
care and treatment (11) 11
cells (11) 11
chemicals and drugs (11) 11
diabetes (11) 11
dipeptidyl-peptidase iv inhibitors - therapeutic use (11) 11
heterocyclic compounds, 2-ring (11) 11
nitric oxide synthase type ii (11) 11
dogs (10) 10
enzyme inhibitors - therapeutic use (10) 10
gene expression (10) 10
kinases (10) 10
molecular structure (10) 10
protein kinase inhibitors - pharmacology (10) 10
pyrans - therapeutic use (10) 10
therapy (10) 10
young adult (10) 10
antineoplastic agents - therapeutic use (9) 9
article (9) 9
cell survival - drug effects (9) 9
chemistry (9) 9
enzyme inhibitors - pharmacology (9) 9
health aspects (9) 9
medicine (9) 9
abridged index medicus (8) 8
cancer therapies (8) 8
cell biology (8) 8
chemotherapy (8) 8
clinical trials (8) 8
discovery (8) 8
drug therapy, combination (8) 8
hypoglycemic agents - therapeutic use (8) 8
inflammation (8) 8
medicine, general & internal (8) 8
mutation (8) 8
patients (8) 8
pharmacology (8) 8
piperazines - pharmacology (8) 8
pyrimidines - therapeutic use (8) 8
safety (8) 8
science (8) 8
signal transduction (8) 8
sulfonamides - therapeutic use (8) 8
toxicology (8) 8
type 2 diabetes (8) 8
amidines - pharmacology (7) 7
cell cycle (7) 7
dosage and administration (7) 7
efficacy (7) 7
endocrinology & metabolism (7) 7
heart failure - drug therapy (7) 7
identification (7) 7
ono-1714 (7) 7
phosphorylation (7) 7
protein kinase inhibitors - therapeutic use (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 2014, Volume 20, Issue 1, pp. 29 - 36
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 01/2015, Volume 35, Issue 3, pp. 1199 - 1210
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2016, Volume 113, Issue 47, pp. 13456 - 13461
Oncogenic activation of protein kinase drives tumor growth by promoting mitogen-activated protein kinase (MAPK) pathway signaling. Because oncogenic mutations... 
BRAF | Targeted therapy | Lung | Cancer | DABRAFENIB | targeted therapy | MULTICENTER | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | OPEN-LABEL | PROLIFERATION | MELANOMAS | DEPENDENCE | lung | RESISTANCE | cancer | MUTATIONS | PROGRESSION | Lung Neoplasms - drug therapy | Humans | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Gene Knockdown Techniques | Heterocyclic Compounds, 2-Ring - adverse effects | Heterocyclic Compounds, 2-Ring - therapeutic use | Female | Antineoplastic Agents - pharmacology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Treatment Outcome | Heterocyclic Compounds, 2-Ring - pharmacokinetics | Enzyme Activation - drug effects | Mice, SCID | Mutation - genetics | Sulfonamides - pharmacology | Mechanistic Target of Rapamycin Complex 1 - metabolism | Sulfonamides - pharmacokinetics | Heterocyclic Compounds, 2-Ring - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Sulfonamides - adverse effects | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Biological Sciences
Journal Article
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 06/2014, Volume 89, Issue 4, pp. 536 - 544
Activation of T-type Ca channels contributes to nociceptive signaling by facilitating action potential bursting and modulation of membrane potentials during... 
Dorsal root ganglion | T-type Ca2+ channels | Neuropathic pain | Nociceptive pain | ACTIVATION | SODIUM | ANTAGONIST | INJURY | ALLODYNIA | MODEL | SENSORY NEURONS | POTENT | GENE | TARGETS | PHARMACOLOGY & PHARMACY | Calcium Channel Blockers - adverse effects | Humans | Calcium Channel Blockers - therapeutic use | Neuralgia - metabolism | Biological Availability | Male | Nociceptive Pain - drug therapy | Peripheral Nerves - drug effects | Dose-Response Relationship, Drug | Heterocyclic Compounds, 2-Ring - adverse effects | Nociceptive Pain - metabolism | Calcium Channels, T-Type - metabolism | Calcium Channels, T-Type - chemistry | Heterocyclic Compounds, 2-Ring - therapeutic use | Peripheral Nerves - cytology | Behavior, Animal - drug effects | Calcium Channels, T-Type - genetics | Peripheral Nerves - metabolism | Disease Models, Animal | Recombinant Proteins - metabolism | Nerve Tissue Proteins - antagonists & inhibitors | Chronic Pain - drug therapy | Cells, Cultured | Rats | Recombinant Proteins - chemistry | Heterocyclic Compounds, 2-Ring - pharmacokinetics | Calcium Channel Blockers - pharmacology | Sulfonamides - pharmacology | Blood-Brain Barrier - drug effects | Nerve Tissue Proteins - genetics | Rats, Sprague-Dawley | Neuralgia - drug therapy | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Heterocyclic Compounds, 2-Ring - pharmacology | Nerve Tissue Proteins - metabolism | Chronic Pain - metabolism | Animals | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Calcium Channel Blockers - pharmacokinetics | Care and treatment | Pain | Index Medicus
Journal Article
Journal Article
by Lv, JH and Wu, JD and He, F and Qu, Y and Zhang, QQ and Yu, CG
CURRENT MEDICINAL CHEMISTRY, ISSN 0929-8673, 2018, Volume 25, Issue 42, pp. 5847 - 5859
Journal Article
JAMA, ISSN 0098-7484, 12/2015, Volume 314, Issue 21, pp. 2251 - 2262
Journal Article
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, ISSN 1552-5260, 2014, Volume 10, Issue 5, pp. S411 - S419
Abstract Alzheimer's disease (AD) is characterized by formation of neuritic plaque primarily composed of a small filamentous protein called amyloid-β peptide... 
Neurology | Animal model | Melatonin | CNS | Liver damage | Drug trial | Side effects | Demyelination | ROS | Aging | Brain disorder | Neuronal death | Sialylation | Human studies | Secretase | Dementia | ALPHA-2,6-SIALYLTRANSFERASE | CLEAVAGE | INDUCED LIVER-INJURY | CLINICAL NEUROLOGY | LEARN MODEL | MICE | MECHANISMS | AMYLOID PRECURSOR PROTEIN | ALZHEIMERS BETA-SECRETASE | GENE | DISEASE | Amyloid Precursor Protein Secretases - genetics | Humans | Aspartic Acid Endopeptidases - genetics | Liver - physiopathology | Heterocyclic Compounds, 2-Ring - adverse effects | Protease Inhibitors - pharmacology | Liver - drug effects | Heterocyclic Compounds, 2-Ring - therapeutic use | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | Disease Models, Animal | Picolinic Acids - pharmacology | Alzheimer Disease - physiopathology | Aspartic Acid Endopeptidases - antagonists & inhibitors | Brain - physiopathology | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Nootropic Agents - adverse effects | Heterocyclic Compounds, 2-Ring - pharmacology | Mice, Knockout | Brain - drug effects | Amyloid Precursor Protein Secretases - metabolism | Picolinic Acids - adverse effects | Animals | Models, Biological | Picolinic Acids - therapeutic use | Aspartic Acid Endopeptidases - metabolism | Amyloid Precursor Protein Secretases - antagonists & inhibitors | Nootropic Agents - pharmacology | Alzheimer's disease | Analysis | Index Medicus
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 10/2017, Volume 33, Issue 10, pp. 1861 - 1868
Journal Article